SOVALDI Drug Patent Profile

When do Sovaldi patents expire, and when can generic versions of Sovaldi launch?

Sovaldi is a drug marketed by Gilead Sciences Inc and is included in two NDAs. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and sixty-eight patent family members in forty-nine countries.

The generic ingredient in SOVALDI is sofosbuvir. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sofosbuvir profile page.

DrugPatentWatch^® Generic Entry Outlook for Sovaldi

Sovaldi was eligible for patent challenges on December 6, 2017.

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for SOVALDI

International Patents:	368
US Patents:	9
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SOVALDI

Paragraph IV (Patent) Challenges for SOVALDI

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SOVALDI	Tablets	sofosbuvir	400 mg	204671	2	2017-12-06

US Patents and Regulatory Information for SOVALDI

SOVALDI is protected by nine US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	SOVALDI	sofosbuvir	TABLET;ORAL	204671-001	Dec 6, 2013		RX	Yes	Yes	8,618,076*PED				Y
Gilead Sciences Inc	SOVALDI	sofosbuvir	TABLET;ORAL	204671-001	Dec 6, 2013		RX	Yes	Yes	8,580,765*PED				Y
Gilead Sciences Inc	SOVALDI	sofosbuvir	TABLET;ORAL	204671-001	Dec 6, 2013		RX	Yes	Yes	8,889,159*PED				Y

International Patents for SOVALDI

When does loss-of-exclusivity occur for SOVALDI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Regional IP Organization (ARIPO)

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Montenegro

New Zealand

Peru

Philippines

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SOVALDI around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2017057230
Croatia	P20140667
Morocco	36906

Supplementary Protection Certificates for SOVALDI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2203462	CA 2014 00061	Denmark		PRODUCT NAME: SOFOSBUVIR; REG. NO/DATE: EU/1/13/894/001-002 20140116
2203462	122014000108	Germany		PRODUCT NAME: SOVALDI (SOFOSBUVIR); NAT. REGISTRATION NO/DATE: EU /1/13/894 20140116; FIRST REGISTRATION: EU EU/1/13/894 20140116
2203462	92600	Luxembourg		PRODUCT NAME: SOVALDI (SOFOSBUVIR); AUTHORISATION NUMBER AND DATE: EU/1/13/894(001-002) - SOVALDI - SOFOSBUVIR 20140117

SOVALDI (SOFOSBUVIR) Patent Landscape and Investment Fundamentals

Last updated: February 19, 2026

SOVALDI (sofosbuvir) is an orally administered nucleotide analog inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. Its development and patent protection by Gilead Sciences have significantly reshaped the HCV treatment market, presenting a complex investment scenario driven by patent exclusivity, market penetration, and evolving therapeutic landscapes.

What is the Current Patent Status of SOVALDI?

Gilead Sciences holds a comprehensive portfolio of patents covering SOVALDI, encompassing its composition of matter, manufacturing processes, and methods of use. The primary composition of matter patent for sofosbuvir has expired in key markets, shifting the patent focus to secondary patents and formulation technologies.

• Composition of Matter: The foundational U.S. patent covering sofosbuvir (U.S. Patent No. 8,900,903) expired on June 22, 2024. Similar expirations have occurred or are imminent in other major jurisdictions. [1]
• Manufacturing Processes: Patents related to the synthesis of sofosbuvir and its intermediates remain critical. For example, U.S. Patent No. 8,410,274, covering a key synthetic route, had a potential expiration in 2027. [2]
• Formulations and Polymorphs: Secondary patents covering specific salt forms, crystalline structures (polymorphs), and formulations designed to improve bioavailability or stability continue to provide some level of protection. These patents often have later expiration dates, extending exclusivity for specific delivery methods or product variations.
• Method of Use Patents: Patents claiming specific therapeutic regimens, such as combination therapies involving sofosbuvir, also contribute to the patent estate.

The expiration of primary patents opens the door for generic competition. However, the complex chemistry involved in sofosbuvir synthesis and the existence of numerous secondary patents can create barriers to entry for generic manufacturers. The validity and enforceability of these secondary patents are subject to ongoing legal challenges.

What is the Market Penetration and Competitive Landscape for SOVALDI?

SOVALDI, often used in combination with other agents, revolutionized HCV treatment by offering a highly effective, pan-genotypic, and shorter-duration cure. Its market penetration has been substantial, leading to a significant decline in the prevalence of HCV infection in treated populations.

• Market Dominance: At its peak, SOVALDI, particularly in combination regimens like HARVONI (ledipasvir/sofosbuvir) and EPCLUSSA (velpatasvir/sofosbuvir), captured a dominant share of the global HCV market.
• Competition:
  • Direct Generics: With the expiration of key patents, generic versions of sofosbuvir are emerging. These are expected to significantly reduce pricing and capture market share, particularly in price-sensitive markets.
  • Rival Direct-Acting Antivirals (DAAs): While SOVALDI was a pioneering DAA, other pharmaceutical companies have developed their own DAA regimens. Examples include AbbVie's MAVYRET (glecaprevir/pibrentasvir) and Merck's ZEPATIER (elbasvir/grazoprevir). These drugs compete based on efficacy across different genotypes, duration of treatment, and safety profiles.
  • Evolving Treatment Paradigms: The focus is shifting from treating active infections to preventing new infections and managing the long-term consequences of liver disease. This evolution can impact the overall demand for curative therapies.

The market for HCV treatment has matured considerably since SOVALDI's introduction. The initial surge in demand for curative therapies has plateaued as the pool of treatable patients shrinks. Generic competition is poised to further fragment the market and drive down prices.

What are the Key Financials and Revenue Drivers for SOVALDI?

SOVALDI and its associated combination products have generated substantial revenue for Gilead Sciences, representing a significant commercial success in antiviral therapeutics.

• Peak Sales: Gilead reported peak annual sales for sofosbuvir-containing products in the mid-2010s, reaching tens of billions of U.S. dollars. For instance, in 2015, Gilead’s HCV franchise, driven by HARVONI and SOVALDI, achieved over $19 billion in revenue. [3]
• Revenue Decline: As expected with patent expirations and the introduction of generic alternatives and new competitors, revenue from sofosbuvir-based therapies has been declining. This decline is a natural part of the drug lifecycle.
• Licensing and Royalty Agreements: Gilead has entered into voluntary licensing agreements with generic manufacturers in low- and middle-income countries. These agreements allow for the production of affordable generic versions in exchange for royalties, providing broader access while still generating revenue. [4]
• Profitability: Despite declining revenues, the high profit margins associated with the initial exclusivity period allowed for significant investment in R&D and diversification of Gilead's pipeline. The cost of goods for sofosbuvir is relatively low once manufacturing processes are optimized.

The financial trajectory of SOVALDI reflects a classic blockbuster drug lifecycle: rapid market penetration, peak sales, and subsequent decline due to generic competition and market maturation.

What are the Regulatory Considerations and Approvals for SOVALDI?

SOVALDI has undergone rigorous review and received approval from major regulatory bodies worldwide, facilitating its widespread adoption.

• FDA Approval: Sofosbuvir was first approved by the U.S. Food and Drug Administration (FDA) in December 2013 as SOVALDI for the treatment of chronic HCV infection. [5]
• EMA Approval: The European Medicines Agency (EMA) granted marketing authorization in January 2014. [6]
• Global Registrations: Approvals followed in numerous other countries, including Japan, Canada, and Australia, enabling global commercialization.
• Combination Product Approvals: Gilead subsequently secured approvals for fixed-dose combinations incorporating sofosbuvir, such as HARVONI (sofosbuvir/ledipasvir) and EPCLUSSA (velpatasvir/sofosbuvir), further solidifying its market position.
• Post-Market Surveillance: Like all approved drugs, SOVALDI and its combinations are subject to post-market surveillance to monitor for adverse events and efficacy in real-world settings.

Regulatory approvals were a critical catalyst for SOVALDI's market success, establishing its safety and efficacy profile for treating a serious public health condition.

What are the Key Risks and Opportunities for SOVALDI Investors?

The investment landscape for SOVALDI is characterized by both diminishing returns from its exclusivity period and emerging opportunities related to its established efficacy and manufacturing expertise.

Risks:

• Generic Erosion: The primary risk is the ongoing and accelerating erosion of market share and pricing power due to the availability of low-cost generic sofosbuvir.
• Market Saturation: The HCV market has treated a significant portion of the infected population, leading to a shrinking addressable market for new curative therapies.
• Competition from Next-Generation Therapies: While SOVALDI was groundbreaking, newer DAAs and potentially novel therapeutic approaches (e.g., immune modulation, curative vaccines) could emerge, further commoditizing the existing treatment landscape.
• Patent Litigation: Gilead faces ongoing legal challenges regarding the validity and infringement of its secondary patents, which could lead to further weakening of its intellectual property protection.
• Pricing Pressures: Healthcare systems globally are exerting pressure on drug prices, which will continue to impact the profitability of all HCV treatments, including generics.

Opportunities:

• Global Access Expansion: Voluntary licensing agreements and the availability of affordable generics offer opportunities to expand treatment to underserved populations in developing countries, driving volume sales.
• Manufacturing Expertise: Gilead possesses significant expertise in the complex manufacturing of sofosbuvir. This expertise could be leveraged for contract manufacturing or the development of next-generation antivirals.
• Combination Therapies and Lifecycle Management: While primary patents expire, there may be opportunities to develop new formulations or combination products with improved efficacy or convenience that could capture residual market share or address specific patient sub-groups, albeit with shorter patent protection windows.
• Diversification: Gilead's experience with SOVALDI provides a template for developing and commercializing other high-impact antiviral therapies, enabling diversification beyond HCV.
• Infrastructure for Viral Hepatitis Treatment: The infrastructure built around SOVALDI's launch and distribution can be repurposed for other viral diseases and public health initiatives.

Investing in SOVALDI at this stage requires a nuanced understanding of the drug lifecycle and the dynamics of the generic pharmaceutical market. The focus shifts from capturing peak exclusivity profits to managing a mature product and leveraging manufacturing and R&D capabilities.

---

Key Takeaways

• SOVALDI's primary composition of matter patents have expired in key markets, allowing for generic entry.
• Gilead Sciences holds secondary patents covering manufacturing processes, formulations, and methods of use that continue to offer some degree of protection.
• SOVALDI and its combination products achieved substantial market penetration, leading to significant revenue generation but also a shrinking addressable market.
• The competitive landscape includes generic sofosbuvir, other DAA regimens, and evolving treatment paradigms.
• Revenue from SOVALDI-based therapies is declining due to generic competition and market maturation.
• Risks for investors include generic erosion, market saturation, and competitive pressures. Opportunities lie in global access expansion through licensing, leveraging manufacturing expertise, and potential lifecycle management.

---

Frequently Asked Questions

1. When did the primary patent for SOVALDI expire in the United States? The U.S. patent (U.S. Patent No. 8,900,903) covering the composition of matter for sofosbuvir expired on June 22, 2024.

2. What is the impact of voluntary licensing agreements on SOVALDI's market? Voluntary licensing agreements allow for the production of affordable generic versions of sofosbuvir in low- and middle-income countries, expanding access and generating royalty revenue for Gilead while also contributing to the commoditization of the drug globally.

3. Are there still effective patent protections for sofosbuvir-based treatments? While primary composition of matter patents have expired, Gilead maintains secondary patents related to manufacturing processes, specific formulations, and methods of use that can extend some level of exclusivity or create barriers to entry for generic competitors.

4. What are the main competitors to SOVALDI? Competitors include generic versions of sofosbuvir, as well as other direct-acting antiviral regimens from companies like AbbVie (MAVYRET) and Merck (ZEPATIER).

5. What is the current revenue trend for SOVALDI? Revenue for SOVALDI and related combination products is declining as a result of patent expirations, generic competition, and a maturing market for hepatitis C treatments.

---

Citations

[1] U.S. Patent No. 8,900,903. (2015). Prodrugs of nucleoside analogues. United States Patent and Trademark Office. [2] U.S. Patent No. 8,410,274. (2013). Process for the preparation of 2′-deoxy-2′-fluoro-2′-methyl-uridine-5′-O-phosphate compounds. United States Patent and Trademark Office. [3] Gilead Sciences, Inc. (2016). Form 10-K Annual Report. U.S. Securities and Exchange Commission. [4] Gilead Sciences, Inc. (2014). Gilead Sciences and the Medicines Patent Pool Announce Landmark Agreement to Expand Access to Treatment for Hepatitis C in Developing Countries. (Press Release). [5] U.S. Food and Drug Administration. (2013). FDA approves Sovaldi to treat chronic hepatitis C infection. (Press Release). [6] European Medicines Agency. (2014). Sovaldi. European Medicines Agency.